Venneos develops and markets the CAN-Q, a silicon chip–based imaging system that analyses biological cells by detecting electrical signals generated by cells grown on the chip and rendering them as microscopy-like images. The technology can identify cellular changes such as alterations in cell adhesion that other technologies cannot detect. Its systems are used in research areas including tumour biology, immunology, pharmacology and drug development. The company plans to use new funding to consolidate its market entry and to prepare new product generations. Venneos also intends to further develop the technology toward additional potential applications in pharmaceuticals, cosmetics and chemistry. Founded in 2014 as a spin-off of the Max Planck Society and based in Stuttgart, Germany, the company recently closed a Series A financing of undisclosed size. Venneos is developing a silicon-chip-based imaging system for analysis of biological cells that uses an innovative measurement approach to detect cellular changes not visible with other technologies. The company is a spin-off from the Max Planck Society, founded by Jonas Lehmann, and is based in Stuttgart, Germany. It is working with pilot customers to further develop its prototype toward a market-ready product. Venneos plans to use recently raised funds to finish product development and prepare market entry for the first product generation. The team is actively recruiting employees at the intersection of physics, electrical engineering, computer science and biology to support development. Financially, the company has secured seed backing to advance its prototype and commercialization efforts.

Total raised

$1M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2015